Congratulations! The research team of Xiamen University conducted a high-quality follow-up studyConfirmed the only hepatitis E vaccine in the worldAvailable for at least 10 yearsEfficient and long-lasting protectionRecently, the relevant research results were published in the international medical authoritative journal The Lancet
Hepatitis E (hepatitis E) is an inflammation of the liver caused by hepatitis E virus (HEV) infection and is one of the most common viral hepatitis forms worldwide. According to the World Health Organization's estimatesGlobally, 20 million people are infected with the hepatitis E virus each year, of which about 3.3 million develop symptoms and cause 70,000 deaths. Due to the widespread misdiagnosis and missed diagnosis of hepatitis E in clinical practiceIts incidence and disease burden are grossly underestimated. In most cases, hepatitis E is self-limited, but the prognosis is poor in special populations such as pregnant women and those with underlying chronic liver disease, which can lead to liver failure and even death.It was independently developed by Xia Ningshao's team at Xiamen UniversityRecombinant hepatitis E vaccine with eco-choninIt is the only hepatitis E prophylactic vaccine in the worldIn 2011 and 2020, it was approved for marketing in China and Pakistan respectively
Since 2007, the research team has initiated a randomized, double-blind, controlled large-scale clinical trial study of Yikonin, and established an acute hepatitis surveillance system covering 205 monitoring sentinel sites in 11 townships and towns in Dongtai City, Jiangsu Province, including municipal hospitals, town health service centers, village health centers, and private clinics, and conducted high-quality follow-up studies for more than 110,000 volunteers participating in clinical trials for up to 10 years.The results of the study showed:Get three shotsmonths) of Ekonin.
The 10-year protection rate is 866%（95%ci 73.0-94.1）
Get two shotsmonths) conanin
It also provides efficient protection.
Protection rate within 30 months.
up to 1000%（95%ci 15.4-100.0) In addition, based on the acute hepatitis surveillance system, the research team included all the resident populations in 11 townships that did not participate in the clinical trial and whose age range was consistent with the trial participants as an external control group to further evaluate the long-term protective effect of econin10-year protection rate of three injections of conaninfor 906%（95%ci 81.9-95.7）Two shots of 10-year protection of Prokonineratefor 899%（95%ci 43.4-99.7）
Overall design of the hepatitis E vaccine clinical study.
Recently, the research results of the hepatitis E vaccine were published in a study titled "Long-term efficacy of a recombinant hepatitis e vaccine in adults: 10-year results from a randomised, double-blind,placebo-controlled,phase 3 trial"*** Published in The Lancet. This is the first time the research team has published a paper in The Lancet in 2010 2010;376(9744):895-902.and in 2015 in the New England Journal of Medicine 2015;372(23):2265-2266.Published 4The third study on the effectiveness of hepatitis E vaccine after 5 years of continuous surveillance. This series of articles provides strong evidence that Econine provides highly effective and long-lasting protection, with a good safety profile and immune durability. (**Fujian Communist Youth League, Soft Branch).EditLin XiaotingAudit:Zheng Wuping, Zhang Min